Video

Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

Author(s):

Loretta J. Nastoupil, MD,Marc S. Hoffmann, MD

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
View More
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity
View More
Related Content
Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
May 16th 2025

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
May 16th 2025

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Breast cancer- stock.adobe.com
May 16th 2025

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

HER2+ Breast Cancer Brain Metastases | Image Credit: ©Sebastian Kaulitzki – stock.adobe.com
May 16th 2025

Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer